Xilio Therapeutics Extends Runway to 2028, Plans XTX501 IND in Mid-2026
XLO•Xilio Therapeutics ended Q1 2026 with $150.3 million cash, extended runway into early 2028 after a $6.0 million development milestone under its AbbVie collaboration. The company plans IND submission for its bispecific PD-1/masked IL-2 candidate XTX501 in mid-2026 and Phase 1 initiation in the second half of 2026, while advancing masked T cell engager programs with new preclinical data for XTX601.
1. First-Quarter Financial Results and Collaboration Milestone
Xilio ended the quarter with $150.3 million in cash and cash equivalents, reflecting the achievement of a $6.0 million development milestone under its AbbVie collaboration that extends its operational runway into early 2028.
2. XTX501 Development Milestones
The bispecific PD-1/masked IL-2 candidate XTX501 is progressing through IND-enabling studies with a planned IND submission in mid-2026, followed by initiation of a Phase 1 trial in the second half of 2026 and initial data in metastatic non-small cell lung cancer in H2 2027.
3. Advances in Masked T Cell Engager Programs
Xilio presented new preclinical data for XTX601 targeting CLDN18.2 showing protease-dependent tumor activation and favorable tolerability in non-human primates; IND-enabling activities for XTX601 and a multi-specific PSMA+STEAP1 engager have commenced, with IND filings targeted for 2027.
